Breaking News
0

Oncomed Pha (OMED)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Oncomed Pha's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.08 +0.06    +1.99%
15:59:59 - Closed. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US68234X1028 
CUSIP: 68234X102
  • Volume: 54,344
  • Bid/Ask: 3.00 / 4.20
  • Day's Range: 2.99 - 3.11
Oncomed Pha 3.08 +0.06 +1.99%

OMED Overview

 
Information about the Oncomed Pha Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close3.02
Day's Range2.99 - 3.11
Revenue38.16M
Open3.03
52 wk Range1.74 - 5.56
EPS - 1.07
Volume54,344
Market Cap115.54M
Dividend (Yield)0 (N/A)
Average Vol. (3m)250,251
P/E RatioN/A
Beta1.77
1-Year Change - 17.87%
Shares Outstanding38,259,662
Next Earnings DateMay 07, 2018
What is your sentiment on Oncomed Pha?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Neutral Sell Strong Sell Sell
Technical Indicators Strong Buy Strong Buy Strong Sell Sell Strong Sell
Summary Strong Buy Buy Strong Sell Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Engulfing Bearish 1W Current
Completed Patterns
Bullish Engulfing 1M 1 Mar 18
Falling Three Methods 1D 1 Apr 18, 2018
Engulfing Bearish 1D 2 Apr 17, 2018

Oncomed Pha News & Analysis

News


Oncomed Pha Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 3.08 3.00 4.20 54,344 +1.99% USD 15:59:59  
  Berlin 2.410 0.000 0.000 0 -5.12% EUR 12:30:00  
  Stuttgart 2.410 0.000 0.000 0 -2.43% EUR 13:49:00  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 172.80 175.39 172.66 -5.04 -2.83% 34.81M 15:59:59  
  Tata Consultancy 3,191.15 3,217.20 3,165.75 +32.05 +1.01% 2.41M 6:29:11  
  Amazon.com 1,556.91 1,568.52 1,539.06 +29.07 +1.90% 6.52M 15:59:59  
  IBM 147.70 149.21 146.62 -1.09 -0.73% 8.09M 15:59:59  
  Alibaba 181.39 183.63 179.52 -1.29 -0.71% 11.99M 15:59:59  
  Facebook 168.10 168.33 165.20 +1.74 +1.05% 22.23M 15:59:59  
  Philip Morris 85.64 94.26 83.50 -15.80 -15.58% 45.57M 15:59:59  
  Sri Rejeki Isman 364 372 356 +8 +2.25% 404.51M 22:47:00  
  Tesla 300.08 301.01 288.55 +6.73 +2.29% 6.09M 15:59:59  
  Netflix 332.70 335.31 326.77 -1.82 -0.54% 8.44M 15:59:59  

Oncomed Pha Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

56

Equity Type

ORD

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
National Futures Association (United States), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) $10000 Start Trading
U.S. Commodity Futures Trading Commission (United States) Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Join the discussion
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email